Background: one of the global public health problem is Thyroid gland disease. More studies are still required to investigate novel markers to specify the prognosis and recovery of the thyroid gland after both internal and external radiation exposure. Methodology: ELISA was used to quantitatively identify the serum level of TSHR-Ab in human blood specimens of Hashimoto’s and Graves’ disease and normal healthy controls. Results: Increased levels of TSHR-Ab (P<0.01) were observed in Graves' disease patients in comparison to the normal healthy controls, it raising significantly (P < 0.01) after one year of curing with anti-thyroid drugs. In contrast, low levels of TSHR-Ab were observed in Hashimoto’s disease cases, and it decreased significantly (P < 0.01) after treatment. Conclusion: serum TSHR-Ab levels in hyperthyroidism and Hypothyroidism patients might be an effective diagnostic marker that increases the immunological response of T cell and immune system, and optimize the chance for detection and remission of autoimmune thyroid disorder
Introduction and Aim: Graves ophthalmopathy is one of the pandemic public health disorders in Iraq. The current investigation attempts to determine the variation in the complete total blood cells on the recovery of individuals with Graves' ophthalmopathy following low and high-dose Radioactive Iodine 131 (RI-131) exposures.
Materials and Methods: The complete blood CBC level in people with Graves' illness and healthy, normal controls were quantitatively identified using the CBC counter. Thyroid stimulating hormone was utilized to compare the recovery of ophthalmopathy patients in comparison to a control group.
Results: In comparison to healthy controls, patients with Graves' ophthalmopathy disease who received 10 mci of RAI-131 had elevated lymphocyte counts (P<0.01). After one year of therapy with antithyroid drugs, lymphocyte counts rose significantly (P<0.01). In contrast, patients treated with 10 mci of RAI-131 experienced a dramatic reduction in monocytes (P< 0.01) over the course of four months. Lymphocytes, monocytes, and platelets were significantly lower in patients with ophthalmopathy after one month of therapy with 20 mci of RAI-131 compared to controls. No significant difference in red blood cells and hemoglobin levels before and after treatment with low and high doses of RAI-131 was observed.
Conclusion: Assessment of lymphocytes, monocytes, granulocytes, and platelets levels in Graves' ophthalmopathy disease patients (GD ophthalmopathy) could be used as an effective diagnostic marker for determining the most effective dose for Graves' ophthalmopathy disease treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.